RFPs

New NIAID BAA: Vaccines, therapeutics, and diagnostics

Dear All, Another AMR-focused BAA (Broad Agency Announcement) is out, now from NIAID! Entitled “2024 NIAID Omnibus Broad Agency Announcement: Development of Medical Countermeasures for Biodefense and Emerging Infectious Diseases,” you can find the solicitation here. The BAA calls for proposals in 3 research areas: Research Area 001: Vaccine Candidates: The goal here is technology platforms

Read More »

NIAID BAA To Support In Vitro Diagnostic Product Development

Dear All, Excitingly, NIAID has released a new BAA (Broad Agency Announcement) entitled “Diagnostics Pre-Clinical Services Program.” Similar to the prior BAA for support of biopharmaceutical product development, this new BAA for diagnostic devices seeks a group who can manage a “multiple award Indefinite Delivery/Indefinite Quantity (IDIQ) type contract” (read that slowly!) and through it offer a comprehensive

Read More »

CDC BAA: Surveillance, endpoints for decolonization, and more…

Dear All, Greetings in the new year! I just tonight picked up on this fascinating BAA (Broad Agency Announcement) from CDC: BAA 75D301-23-R-72545 as described on this general overview webpage: https://sam.gov/opp/15229982f7c348f69fd35e9a0add8aba/view The BAA itself  Timeline: Initial white papers (max 4 pages, see page 76 of the BAA for details) are due by 3 Feb 2023; Invitations for

Read More »

Application calls! ENABLE-2, BARDA BAA! Ho, ho, ho!

Dear All, Two funding opportunities to call to your attention! First, ENABLE-2 has just launched an Open Call for antibacterial programs throughout Europe. The ENABLE-2 platform supports the development of direct-acting systemic antibacterial compounds (potentiator molecules are also in scope, e.g. β-lactamase inhibitors) by providing experimental support and expert advice. The goal of ENABLE-2 is

Read More »

FDA offers 2 fellowships and 3 RFPs! Endpoints, breakpoints, PROs & more!

Dear All, Our colleagues at FDA are planning some serious AMR-related research during 2021-22 with the following fellowships and RFPs. Extended details are available via the links — you can also find brief summaries below my signature or via FDA’s research webpage. Wow! FDA Fellowship #1: A study of ordinal endpoints for antibiotic trials using

Read More »

Jan-Feb meetings; CDC releases Healthcare Epidemiology RFP

Dear All: Happy New Year! I hope everyone was able to take a least a brief break over the holidays. Two things for today. First, there are two meetings in January and one in February that have just popped onto my radar. See the meetings calendar for a pair of Keystone Symposia on the microbiome,

Read More »

Wellcome Trust RFP: Landscape Report on Early antibiotic development

Dear All, The Wellcome Trust Drug-Resistant Infections team wants to understand what researchers in academia and SMEs need to enable them to be better able to make progress with their early antibiotic discovery projects. Although some programs are now in place (e.g., the accelerator support provided by CARB-X), what are the remaining barriers?  To help

Read More »

WHO to create a Priority Pathogen List for Fungi! / RFP to build the list

Dear All, WHO have been thinking about the threat of resistant fungi as well as resistant bacteria. An initial discussion by a small working group on approaches to priority fungal pathogens (April 2020, here’s the link to the report) concluded that Candida auris; azole-resistant Candida spp., azole-resistant Aspergillus fumigatus, Cryptococcus neoformans (& C. gattii), Pneumocystis jirovecii, Mucorales, and potentially Histoplasmosis were

Read More »
Scroll to Top